Biogen’s felzartamab received its first global approval in China for the treatment of multiple myeloma, extending the drug’s availability alongside standard backbones. The approval targets second-line patients receiving felzartamab in combination with lenalidomide and dexamethasone, positioning the monoclonal antibody for uptake in a crowded myeloma market. Meanwhile, Geneseeq’s NTRK fusion detection kit (PanTRKare) gained China NMPA clearance as a companion diagnostic for Vcare PharmaTech’s Velmarto (TRK inhibitor). The clearance links sequencing-based detection to patient selection for NTRK-driven solid tumors, reinforcing the regulatory push for CDx-linked oncology pathways. Taken together, the two approvals show China continuing to mature its oncology regulatory ecosystem for both therapeutics and molecular selection tools—key for companies building registrational evidence and launch-ready reimbursement pathways.